In Silico Docking Studies of Selected Flavonoids - Natural Healing Agents against Breast Cancer

  • Published : 2014.10.23


Background: Breast cancer is the serious health concern in India causing the highest mortality rate in females, which occurs due to uncontrolled cell division and can be metastasize to other parts of the human body. Interactions with estrogen receptor (ER) alpha are mainly responsible for the malignant tumors with regulation of the transcription of various genes as a transcription factor. Most of the drugs currently used for the breast cancer treatment produce various side effects and hence we focused on natural compounds which do not exhibit any toxic effect against normal human cells. Materials and Methods: Structure of human ER was retrieved from the Protein Data Bank and the structures of flavonoid compounds have been collected from PubChem database. Molecular docking and drug likeness studies were performed for those natural compounds to evaluate and analyze the anti-breast cancer activity. Results: Finally two compounds satisfying the Lipinski's rule of five were reported. The two compounds also exhibited highest binding affinity with human ER greater than 10.5 Kcal/mol. Conclusions: The results of this study can be implemented in the drug designing pipeline.


  1. Ariazi EA, Ariazi JL, Cordera F, Jordan VC (2006). Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem, 6, 181-202.
  2. Andrew NF, Binbing Y, Mitchell HG, et al (2011). Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol, 29, 2327-33.
  3. Binkowski TA, Naghibzadeh S, Liang J (2003). CASTp: Computed atlas of surface topography of proteins. Nucleic Acids Res, 31, 3352-55.
  4. Batra P, Sharma AK (2013). Anti-cancer potential of favonoids: recent trends and future Perspectives. Biotech, 3, 439-59.
  5. Benson JR, Jatoi I (2012). The global breast cancer burden. Future Oncol, 8, 697-702.
  6. Berman HM, Battistuz T, Bhat TN, et al (2002). The protein data bank. Acta Crystallogr D Biol Crystallogr, 58, 899-907.
  7. Chi F, Wu R, Zeng Y-C, et al (2013). Post-diagnosis soy food intake and breast cancer survival: a meta-analysis of cohort studies. Asian Pac J Cancer Prev, 14, 2407-12.
  8. Chitrala KN, Yeguvapalli S (2013). Prediction and analysis of ligands against estrogen related receptor alpha. Asian Pac J Cancer Prev, 14, 2371-5.
  9. Dickson RB, Stancel GM (2000). Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr, 27, 135-45.
  10. Dykstra KD, Guo L, Birzin ET, et al (2007). Estrogen receptor ligands. Part 16: 2-Aryl indoles as highly subtype selective ligands for ERalpha. Bioorg Med Chem Lett, 17, 2322-8.
  11. Fabian CJ, Kimler BF (2001). Chemoprevention for high-risk women: tamoxifen and beyond. Breast J, 7, 311-20.
  12. Fuqua SA (2001). The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia, 6, 407-17.
  13. Galluzzo P, Marino M (2006). Nutritional flavonoids impact on nuclear and extranuclear estrogen receptor activities. Genes Nutrition, 1, 161-76.
  14. Izadi P, Noruzinia M, Fereidooni F, Nateghi MR (2012). Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women. Asian Pac J Cancer Prev, 13, 4113-7.
  15. Jarzabek K, Koda M, Kozlowski L, et al (2009). The significance of the expression of ERRalpha as a potential biomarker in breast cancer. J Steroid Biochem Mol Biol, 113, 127-133.
  16. Hayashi S, Eguchi H, Tanimoto K et al (2003). The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat cancer, 10, 193-202.
  17. Hui C, Qi X, Qianyong Z, et al (2013). flavonoids, flavonoid subclasses and breast cancer risk: A meta-analysis of epidemiologic studies. Plus One, 8, 54318.
  18. Karimi Zarchi M, Behtash N, Sekhavat L, Dehghan A (2009). Effects of tamoxifen on the cervix and uterus in women with breast cancer: experience with iranian patients and a literature review. Asian Pac J Cancer Prev, 10, 595-8.
  19. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M (1999). Antiproliferative activity of flavonoids on several cancer cell lines. Biosci Biotechnol Biochem, 63, 896-9.
  20. Kumar P, Bolshette NB, Jamdade VS, et al (2013). Breast cancer status in India. Biomedicine Preventive Nutrition, 3, 177-83.
  21. Limer JL, Speirs V (2004). Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res, 6, 119-27.
  22. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev, 46, 3-26.
  23. Park WC, Jordan VC (2002). Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol Med, 8, 82-8.
  24. Lu H, Chen D, Hu L-P, et al (2013). Estrogen receptor alpha gene polymorphisms and breast cancer risk: a case-control study with meta-analysis combined. Asian Pac J Cancer Prev, 14, 6743-9.
  25. Miller PE, Snyder DC (2012). Phytochemicals and cancer risk: a review of the epidemiological evidence. Nutr Clin Pract, 27, 599-612.
  26. Oda A, Kamiyama Y, Yoshida T, et al (2007). Evaluation of docking accuracy and investigations of roles of parameters and each term in scoring functions for protein-ligand docking using Argus lab software. Bull Chem Soc Jap, 80, 1920-5.
  27. Parkkari M, Paakkala AM, Salminen L, Holli K (2003). Ocular side effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol Scand, 81, 495-9.
  28. Pouget C, Lauthier F, Simon A, et al (2001). flavonoids: Structural requirements for antiproliferative activity on breast cancer cells. Bioorg Med Chem Lett, 11, 3095-7.
  29. Pritchard KI (2001). Breast cancer prevention with selective estrogen receptor modulators: a perspective. Ann NY Acad Sci, 949, 89-98.
  30. Ramezani F, Salami S, Omrani MD, Maleki D (2012). CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis. Asian Pac J Cancer Prev, 13, 451-7.
  31. Salih AK, Fentiman IS (2001). Breast cancer prevention: present and future. Cancer Treat Rev, 27, 261-73.
  32. Stapel J, Oppermann C, Richter DU, Ruth W, Briese V (2013). Polyphenol compounds with anti-carcinogenic qualities: Effects of quercetin (flavonol), chrysin (flavon), kaempferol (flavanol), naringenin (flavanon) and hesperidin (flavanoid) on in vitro breast cancer. J Med Plants Res, 7, 2187-96.
  33. Sanaz Hamedeyazdan, Fatemeh F, Simin Sharifi, Nazemiyeh H (2012). Antiproliferative activity of marrubium persicum Extract in the MCF-7 human breast cancer cell line. Asian Pac J Cancer Prev, 13, 5843-8.
  34. Shi J, Ji A, Cao Z, et al (2011). Equol induced apoptosis of human breast cancer MDA-MB-231 cell by inhibiting the expression of nuclear factor-kappaB, Wei Sheng Yan Jiu, 40, 95-8.
  35. Shuzhong Zhang, Xinning Yang, Marilyn E Morris (2004). flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol, 65, 1208-16.
  36. Thomas C, Gustafsson JA (2011). The different roles of ER subtype in cancer biology and therapy. Nature Reviews Cancer, 11, 597-608.
  37. Toniti W, Suthiyotha N, Puchadapirom P, Jenwitheesuk E (2011). Binding capacity of ER-${\alpha}$, ligands and SERMs: comparison of the human, dog and cat. Asian Pac J Cancer Prev, 12, 2875-9.
  38. Xu C-Y, Jiang Z-N, Zhou Y, Li J-J, Huang L-M (2013). Estrogen receptor ${\alpha}$ roles in breast cancer chemoresistance. Asian Pac J Cancer Prev, 14, 4049-52.

Cited by

  1. Inhibitory Aromatase Effects of Flavonoids from Ginkgo Biloba Extracts on Estrogen Biosynthesis vol.16, pp.15, 2015,
  2. Sequence to Structure Approach of Estrogen Receptor Alpha and Ligand Interactions vol.16, pp.6, 2015,
  3. Types of Cancers Prevailing in Pakistan and their Management Evaluation vol.16, pp.9, 2015,
  4. Preparation and Evaluation of Chrysin Encapsulated in PLGA-PEG Nanoparticles in the T47-D Breast Cancer Cell Line vol.16, pp.9, 2015,
  5. Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study vol.16, pp.9, 2015,
  6. Structure Based docking studies towards exploring potential anti-androgen activity of selected phytochemicals against Prostate Cancer vol.7, pp.1, 2017,
  7. Artonin E and Structural Analogs from Artocarpus Species Abrogates Estrogen Receptor Signaling in Breast Cancer vol.21, pp.7, 2016,
  8. Nanoscale modification of chrysin for improved of therapeutic efficiency and cytotoxicity pp.2169-141X, 2018,